Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Travoprost APS 40 micrograms/ml eye · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Travoprost APS | EXPERIMENTAL | Travoprost APS 40 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days |
| XALATAN | ACTIVE_COMPARATOR | Latanoprost 50 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days |
| Name | Type | Description |
|---|---|---|
| Travoprost APS 40 micrograms/ml eye drop solution | DRUG | non-BAK (benzalkonium chloride) medication |
| Latanoprost 50 micrograms/ml eye drop solution | DRUG | BAK-preserved medication |
Inclusion Criteria: * Must have a clinical diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component), or ocular hypertension in at least 1 eye. * Must be willing and able to discontinue use of any topical ocular medication other than the study medication f...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
Travoprost APS 40 micrograms/ml eye is an investigational small molecule being developed for the treatment of open angle glaucoma. It is administered as an eye drop and is currently in Phase 3 clinical development. The drug is being studied in patients with open angle glaucoma and ocular hypertension.
Travoprost APS 40 micrograms/ml eye is a prostaglandin analogue that works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. This mechanism helps to lower pressure within the eye, which is the primary goal in treating open angle glaucoma.
Travoprost APS 40 micrograms/ml eye is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is a global medical device company specializing in eye care products, including surgical equipment and vision care.
Travoprost APS 40 micrograms/ml eye is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug is being evaluated for its efficacy and safety in treating open angle glaucoma.
Travoprost APS 40 micrograms/ml eye has one completed Phase 3 clinical trial registered as NCT00892762, titled 'Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health.' This randomized, double-blind, active-controlled study enrolled 434 participants with open angle glaucoma or ocular hypertension.
Travoprost APS 40 micrograms/ml eye is not the same as Xalatan. In the clinical trial NCT00892762, Travoprost APS was compared against Xalatan as an active control. Xalatan is a different prostaglandin analogue used to treat elevated intraocular pressure, while Travoprost APS is the investigational drug being studied.